By Fineline Cube 
Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by Apricot Capital, with participation from Qiming Venture Partners. The funds will primarily support the development of the company’s preclinical extrahepatic targeted nucleic acid platform and pipeline, marking a significant step in advancing innovative therapies for non-liver tissues.
Addressing Challenges in Extrahepatic Targeted Delivery
While liver-targeting delivery methods like GalNAc have reached maturity, extrahepatic targeting poses substantial challenges, including receptor selection, ligand conjugation, tissue absorption efficiency, and safety. Vivatides Therapeutics has overcome these bottlenecks by developing a differentiated extrahepatic delivery platform with a unique underlying design. This proprietary technology aims to address the limitations of current approaches and unlock new possibilities for targeted nucleic acid therapies.
A Team with Deep Expertise in Nucleic Acid Innovation
Founded in 2025, Vivatides Therapeutics is led by an international core team with extensive R&D experience at leading nucleic acid companies such as Arrowhead, Ionis, Alnylam, and Dicerna. Prior to founding Vivatides, the team members played key roles in developing multiple extrahepatic pipelines, several of which are now in clinical development. This hands-on expertise positions Vivatides as one of the few companies with proven technical leadership in both ASO (antisense oligonucleotide) and siRNA (small interfering RNA) therapies for extrahepatic targets.-Fineline Info & Tech